Lipid nanoparticles for targeted siRNA delivery – going from bench to bedside

Abstract: This review covers the basic aspects of small interfering RNA delivery by lipid nanoparticles (LNPs) and elaborates on the current status of clinical trials for these systems. We briefly describe the roles of all LNP components and possible strategies for their improvement. We also focus on the current clinical trials using LNP-formulated RNA and the possible outcomes for therapy in the near future. Also, we present a critical analysis of selected clinical trials that reveals the common logic behind target selection. We address this review to a wide audience, especially to medical doctors who are interested in the application of RNA interference–based treatment platforms. We anticipate that this review may spark interest in this particular audience and generate new ideas in target selection for the disorders they are dealing with.

Keywords: RNA therapeutics, siRNA, mRNA, lipid nanoparticle, targeted delivery, clinical trial

Introduction

Development of novel therapeutics is a ceaseless process as public health becomes more and more valuable in the society. Today, small molecules and monoclonal antibodies are main players in drug development, but RNA therapeutics is foreseen to soon become a breakthrough technology. RNA therapeutics is advantageous when current techniques fail due to inefficiency of the treatment, complicated schemes of therapy, or newly developed resistance to the drug due to mutational escape. The Food and Drug Administration has recognized the importance of this new approach: two oligonucleotide-based drugs are already approved (pegaptanib and kynamro). Fast track status has been awarded to studies testing small interfering RNAs (siRNAs) for viral infections, and efficacy studies are being conducted in nonhuman primates, while the safety studies are performed in humans. This siRNA-based revolutionary approach can soon come to the market, depending on the results of several active Phase III clinical trials. This review will focus on siRNA delivery by lipid nanoparticles (LNPs) and the current status of clinical trials for these systems. In the first section, we will describe the different components forming the LNPs and discuss the possible routes for their improvement. We will then report current clinical trials using LNP-formulated RNA and the possible outputs for therapy in the near future. Finally, we will present a critical analysis of selected clinical trials, which would reveal the common logic behind target selection, and demonstrate some examples of lessons learned from failed trials.

LNPs for RNA delivery: structure and requirements

During the last 5 years, siRNA, microRNA (miRNA) mimetics, antagonirs, and messenger RNA (mRNA) have made tremendous progress as potential therapeutics. However, targeted delivery and endosome escape still remain the major challenges for...
RNA drug development. siRNAs are short (19–21 nucleotide), double-stranded RNAs that enter the natural RNA interference (RNAi) mechanism and degrade complementary mRNAs by the use of complicated protein machinery. As a result, one can reversibly knock down in vivo a protein of interest (80%–90% decrease) at doses of siRNAs approximately 1–2 mg/kg. Antagomirs sterically block miRNAs by the formation of duplexes, which influences posttranscriptional regulation of gene expression.11 Artificial mRNAs are used for controlled transient expression of proteins in cancer immunotherapeutics and vaccination.10 Today, there are several efficient systemic delivery strategies for RNAs that are presently in clinical trial: LNPs, N-acetylgalactosamine conjugates, and dynamic polyconjugates (DPCs).6,12,13 Also, there are techniques for local delivery or topical application of RNAs.14,15

Delivery systems based on cationic lipids (liposomes and LNPs) are the most commonly used nonviral vectors for RNA delivery, both in academic studies and clinical trials.16–18 The basic principle of LNP formation is self-assembly that is an integral property of smart nanosystems. Hundreds of lipids have been developed to improve transfer efficiency and stability and decrease immune response and renal escape. Since the first iterations of LNPs, lipids have evolved a lot; from the common 1,2-dioleoyl-3-trimethylammonium-propane/1,2-dioleoyl-sn-glycero-3-phosphoethanolamine combination to more sophisticated structures (Figure 1), they have become much less toxic and are biodegradable and pH sensitive (smart). From a chemical viewpoint, there are two main structural improvements that make the new lipids more efficient vehicles for siRNA: multiply unsaturated alkyl chains promote significant destabilization of intracellular membrane bilayer,19 while protonation of the ionizable dimethylaminopropyl group only during lysosome maturation improves LNP initial fusion with the membrane.20 Moreover, lipidoids, or lipid-like materials, were shown to be very efficient carriers for siRNA. For example, C12-200 (Figure 1) is suitable for multiple animal species, such as rodents and nonhuman primates.21,22 One of the main benefits of lipidoids is the decreased amount of helper lipids needed for effective delivery.

By themselves, cationic lipids are inadequate delivery vehicles for siRNA, and therefore, the so-called helper lipids should be added to form the LNP.23 Among them are fusogenic phospholipids (Figure 1B), which enhance the transfection activity of LNPs by destabilizing the lipid bilayer structure in cell membranes, and polyethylene glycol (PEG) lipids (Figure 1C), which decrease the immune response by increasing colloidal stability and shielding LNPs from macrophages.24 However, high surface content of PEG lipids decreases cellular internalization of LNPs by hindering membrane destabilization; so, an optimal proportion should

![Figure 1 Structures of lipids used for RNA delivery.](https://www.dovepress.com/)

**Notes:** (A) Cationic lipids and lipidoids. (B) Phospholipids. (C) PEG lipids, cholesterol.

**Abbreviations:** DOPC, 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine; PEG, polyethylene glycol; DOTAP, 1,2-dioleoyl-3-trimethylammonium-propane; DSPC, 1,2-distearoyl-sn-glycero-3-phosphocholine; PEG-C-DMA, 3-N-[[(ω-methoxypoly(ethylene glycol)2000)carbamoyl]-1,2-dimyristyloxy-propylamine; mPEG-DSPE, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[(methoxy(polyethylene glycol)-2000].
be found. To overcome this problem, one can decrease molar percentage or use modified variants of PEG lipids that weakly anchor to LNPs and are gradually lost during circulation.\(^{25}\) Another key component of LNP is cholesterol, which stabilizes nanoparticles by filling the gaps between lipids\(^{26}\) and enhances the activity of cationic lipids.\(^{27}\) A common scheme of siRNA–LNP formation includes several steps. The first step is the formation of complexes of siRNA with ionizable cationic lipids in 40% ethanol solution with low ionic strength and pH approximately 4. As siRNAs are rather short in comparison to plasmids, they should be truly covered by lipids to achieve stable incorporation into LNP. Then, these nucleating structures are covered by helper lipids, cholesterol, and finally by PEG-lipids that lead to the formation of LNPs with embedded siRNA (Figure 2). Most of the parameters such as siRNA:lipids ratio, concentrations, and temperature should be optimized empirically.

To decrease glomerular filtration, renal clearance, and generation of immune response, one should control the size (optimal 50–100 nm) and surface charge of the LNPs. The size of LNPs is controlled mainly by concentration of the components during mixing and the fraction of PEG lipids contained in the mixture. Work performed on LNPs also revealed that neutral carriers are more efficient during circulation in the blood and penetration in tumor tissues, while cationic carriers are preferable during cellular uptake and endosomal escape.\(^{28}\) Indeed, first-generation LNPs were formed during formulation by self-assembly and were disrupted in endosomes, which led to the degradation of RNA molecules in the endosomes rather than RNA release in the cytosol. These results generated the development of more complicated pH-sensitive LNPs that change their charge in endosomes, thus improving RNA escape after penetration into the cell. However, even in this case, only 1%–2% of the total siRNA is released into the cytosol.\(^{29}\) Moreover, approximately 70% of all internalized nanoparticles are rejected outside the cell by recycling.\(^{30}\) Hence, future small molecules developed to enhance the uptake and endosome release of LNPs can really propel the use of RNA therapeutics.\(^{31,32}\) Another prospective effector for LNPs is melittin, a known pore-forming peptide\(^{33}\) that was successfully used for RNA delivery directly\(^ {34}\) or as a masked part of the polymer carrier for RNA.\(^{35}\) Finally, incorporation of metal nanoparticles in LNPs could improve disruption of the endosome membrane under alternating magnetic fields.\(^{36}\)

As we mentioned earlier, the main problem in targeted delivery of RNA, besides the escape from endosomes after cell penetration, is the specific and efficient delivery to the appropriate cell types of the tissue of interest. Attachment of targeting molecules (N-acetylgalactosamine—a ligand of ASGPR receptor,\(^ {24,37}\) hyaluronan that specifically binds the CD44 receptor\(^ {38}\)) and antibodies\(^ {39–42}\) to the nanoparticle is the main concept presently used for directing the LNP to the cell or the tissue of interest.

Native siRNAs are easily degraded by nucleases in biological fluids. So, considerable chemical modification for in vivo applications using siRNAs is a necessity. The most common modifications for siRNA used in LNP delivery are 2′,3′-O-methyl, 2′-fluoro and phosphorothioate (Figure 3). More intricate modifications are used to increase RNA stability in

![Figure 2 Schematic structure of lipid nanoparticles. Abbreviation: PEG, polyethylene glycol.](assets/figure2.png)

![Figure 3 Structures of modified RNA.](assets/figure3.png)
conjugates, as RNA itself is less sterically protected than when enveloped by LNP.\textsuperscript{43} In most cases, data obtained on the activity of modified siRNA in vitro are easily translated in vivo; however, in vivo toxicity and siRNA stability (degradation pattern) should be thoroughly studied.

Most of the LNP-formulated siRNAs and mRNAs are administered by intravenous (IV) injection. However, high stability of LNPs allows for subcutaneous administration in the case of delivery to the liver,\textsuperscript{44} which significantly simplifies their future application as therapeutics.

### Toxicity and immunogenicity of siRNA–LNP in Phase I clinical trials

LNPs are the carriers most often used in clinical trials for siRNA-based therapeutics, not only because of their obvious advantages over other existing delivery vehicles, such as ease of preparation and versatility, but also their biocompatibility, biodegradability, and accumulated record of clinical use. Unfortunately, being synthetic and quite “unnatural”, lipids can be toxic and promote immune response at high doses.\textsuperscript{45} These negative effects are significantly lower in the newer versions of lipids and polymers; however, immunogenicity and toxicity of LNPs can still be an obstacle in clinical application, particularly if the required dose is high or if frequent repetitive application is required.

Novel lipids selected by advanced screening\textsuperscript{13,21,46} facilitate clinical trials, but application of similar LNPs does not guarantee the success of novel siRNA therapeutics. For example, the clinical trial for the treatment of hypercholesterolemia using siRNA/LNPs to target ApoB production was terminated due to immunogenicity (NCT00927459). On the contrary, no serious adverse effects were reported in the ALN-PCS02 trial with similar LNP by Alnylam Pharmaceuticals, targeting the proprotein convertase subtilisin/kexin type 9 (PCSK9) transcript (NCT01437059). This recent study is particularly encouraging, as it demonstrates that selection of proper lipid components can overcome earlier reported toxicity, immunogenicity such as the release of tumor necrosis factor-\(\alpha\), interferon-\(\gamma\), interleukin-6, interleukin-12, and damage to the liver tissue resulting in elevated levels of transaminases (alanine transaminase, aspartate transaminase), leukopenia, and thrombocytopenia.\textsuperscript{47–49}

We want to emphasize that application of siRNA/LNP in clinical studies should be based on predictive animal models and understanding the physiology. Also, sharing data is a key point for successful translation of LNP from a bench scale into clinical studies.

### Principles and examples of RNA target selection for LNP–siRNA therapeutics

Intervention with RNAi is based either on direct loss of function or gain of function. In the first case, RNAi causes downregulation of overproduced proteins that cause pathological changes, for example, reducing the production of angiotensinogen by the liver during preeclampsia. Gain of function of specific protein can be achieved by removal of negative regulatory feedback. Both approaches are currently being tested in clinical trials in three major areas: antiviral approaches, anticancer therapies, and genetic disorders, but the success of the therapy relies on careful target selection. In this section, we will discuss the common logic behind efficient target selection. All data on current clinical trials of siRNA/LNP are summarized in Table 1.

Application of the RNAi approach to combat viral infections has several specific advantages. First, targeting several gene products simultaneously will reduce the possibility of accumulated mutations and reinfection with the stable form of the virus. Second, reducing the expression of cell surface antigens, such as hepatitis B surface antigen in hepatitis B virus (HBV), diminishes immunosuppression and activates the T-cell response, leading to seroconversion and eventually functional cure.\textsuperscript{30} Finally, fast response to new strains of viruses by minimal changes of siRNA sequences can be provided with this technology.

Promising results have been obtained using siRNA-loaded LNPs in treating liver cancer. Existing LNP-based delivery protocols point toward clinically important siRNA targets expressed in the liver. Also, clinical studies in humans demonstrated little adverse effect to LNPs in the liver or any general immune response to modified siRNA. Therefore, the success of siRNA drug development depends mostly on the careful selection of the drug target expressed in the liver.

Most of the studies targeting cancer-associated pathways with an RNAi approach are at the discovery stage and some researchers express doubts about the accessibility of nonhepatic tumors to LNP-formulated RNAs. Increased permeability of the blood vessels for proteins and particles <20 nm unfortunately does not translate into permeability to LNPs. Hence, the efficacy of local delivery in the tumor remains a challenge. Target selection in cancer is also not as straightforward as it may seem to be. Numerous pathways are activated in cancer; however, blocking an individual pathway usually does not lead to death of a tumor. Nonetheless, enormous unmet needs and a reduced threshold for acceptable severity
of adverse effects guarantee the interest of pharmaceutical companies in the development of anticancer drugs. Several pharmaceutical companies demonstrated willingness to bring RNAi therapeutics to Phase I/Phase II clinical trials. Currently, these trials provide the much needed hope for aggressive cancers resistant to existing treatment protocols. Continued success depends on the improvement of efficient delivery technologies while maintaining a good safety profile. If successful, this will attract investments needed for Phase III trials.

RNA therapeutics can be used not only for direct inhibition of key genes of interest but also as a helper for small-molecule drugs or monoclonal antibodies. For example, inhibition of Testican-1 by siRNA restores sensitivity to lapatinib in the treatment of human epidermal growth factor receptor 2-positive gastric cancer.\(^\text{50}\) Another interesting example is the simultaneous application of siRNA and 5-fluorouracil in hepatic metastasis of colon cancer, which reduced the incidence of liver metastases.\(^\text{51}\)

### Antiviral therapy

Arbutus Biopharma Corporation recently published the efficacious treatment of macaques in the early stages of infection by

---

**Table 1: Selected clinical trials of siRNA and antisense oligonucleotides**

<table>
<thead>
<tr>
<th>Target</th>
<th>Company</th>
<th>siRNA</th>
<th>Route</th>
<th>Phase</th>
<th>Stage</th>
<th>Clinical trial reference ID</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ebola virus</td>
<td>Arbutus (Tekmira Pharmaceuticals)</td>
<td>TKM-Ebola (TKM-100802)</td>
<td>IV</td>
<td>I</td>
<td>Terminated</td>
<td>NCT02041715</td>
</tr>
<tr>
<td>ZEBOV polymerase, VP24, VP35</td>
<td>Tekmira Pharmaceuticals</td>
<td>TKM-Ebola (TKM-100201)</td>
<td>IV</td>
<td>I</td>
<td>Terminated</td>
<td>NCT01518881</td>
</tr>
<tr>
<td>Hepatitis B virus</td>
<td>Arbutus (Tekmira Pharmaceuticals)</td>
<td>ARB-001467</td>
<td>IV</td>
<td>II</td>
<td>Initiated</td>
<td>NCT02631096</td>
</tr>
<tr>
<td>Hepatic fibrosis</td>
<td>Nitto Denko Corp</td>
<td>ND-L02-s0201</td>
<td>IV</td>
<td>I</td>
<td>Completed</td>
<td>NCT01858935</td>
</tr>
<tr>
<td>Primary liver cancer and other malignancies</td>
<td>Mirna Therapeutics</td>
<td>miR34 mimic MRX34</td>
<td>IV</td>
<td>I</td>
<td>Recruiting</td>
<td>NCT02227459</td>
</tr>
<tr>
<td>Solid tumors with liver metastasis</td>
<td>National Cancer Institute</td>
<td>TKM-080301 (TKM-PLK-1)</td>
<td>IV</td>
<td>I</td>
<td>Completed</td>
<td>NCT01437007</td>
</tr>
<tr>
<td>Neoadjuvant breast cancer</td>
<td>Arbutus (Tekmira Pharmaceuticals)</td>
<td>ALN-PC502</td>
<td>I/I</td>
<td>II</td>
<td>Completed</td>
<td>NCT01262235</td>
</tr>
<tr>
<td>Adrenocortical carcinoma</td>
<td>Pharmaceutical</td>
<td>ALN-PCSSC</td>
<td>SC</td>
<td>I</td>
<td>Active</td>
<td>NCT02191878</td>
</tr>
<tr>
<td>Hepatocellular carcinoma</td>
<td>Dicerna Pharmaceuticals</td>
<td>DCR-MYC</td>
<td>IV</td>
<td>I/II</td>
<td>Completed</td>
<td>NCT02314052</td>
</tr>
<tr>
<td>Solid tumors with liver metastasis</td>
<td>Multiple myeloma</td>
<td>Alnylam Pharmaceuticals</td>
<td>IV</td>
<td>I</td>
<td>Recruiting</td>
<td>NCT02110563</td>
</tr>
<tr>
<td>Non-Hodgkin's lymphoma</td>
<td>MD Anderson Cancer Center</td>
<td>siRNA-EphA2-DOPC</td>
<td>IV</td>
<td>I</td>
<td>Recruiting</td>
<td>NCT01591356</td>
</tr>
<tr>
<td>EPH2</td>
<td>Tekmira Pharmaceuticals</td>
<td>ALN-VSP02</td>
<td>IV</td>
<td>I</td>
<td>Completed</td>
<td>NCT00882180</td>
</tr>
<tr>
<td>Solid tumors with liver metastasis</td>
<td>Tekmira Pharmaceuticals</td>
<td>ALN-VSP02</td>
<td>IV</td>
<td>I</td>
<td>Completed</td>
<td>NCT0158079</td>
</tr>
<tr>
<td>VEGF and KSP</td>
<td>ALN-VSP02</td>
<td>ALN-VSP02</td>
<td>IV</td>
<td>I</td>
<td>Completed</td>
<td>NCT01437059</td>
</tr>
<tr>
<td>Hypercholesterolemia</td>
<td>ALN-VSP02</td>
<td>ALN-VSP02</td>
<td>IV</td>
<td>I</td>
<td>Completed</td>
<td>NCT01437059</td>
</tr>
<tr>
<td>PCSK9</td>
<td>ALN-PC502</td>
<td>ALN-PCSSC</td>
<td>SC</td>
<td>I</td>
<td>Active</td>
<td>NCT01591356</td>
</tr>
<tr>
<td>Type 2 diabetes</td>
<td>IONIS (ISIS)</td>
<td>ISIS 304B01 (ISIS-APOCIIIRx)</td>
<td>IV</td>
<td>II</td>
<td>Terminated</td>
<td>NCT01647308</td>
</tr>
<tr>
<td>Hypertriglyceridemia</td>
<td>Pharmaceuticals</td>
<td>ISIS 304B01 (ISIS-APOCIIIRx)</td>
<td>IV</td>
<td>II</td>
<td>Terminated</td>
<td>NCT01647308</td>
</tr>
<tr>
<td>Familial chylomicronemia syndrome</td>
<td>Pharmaceuticals</td>
<td>ISIS 304B01 (ISIS-APOCIIIRx)</td>
<td>IV</td>
<td>II</td>
<td>Terminated</td>
<td>NCT01647308</td>
</tr>
<tr>
<td>Partial lipodystrophy</td>
<td>Pharmaceuticals</td>
<td>ISIS 304B01 (ISIS-APOCIIIRx)</td>
<td>IV</td>
<td>II</td>
<td>Terminated</td>
<td>NCT01647308</td>
</tr>
<tr>
<td>Lipoprotein lipase deficiency</td>
<td>Pharmaceuticals</td>
<td>ISIS 304B01 (ISIS-APOCIIIRx)</td>
<td>IV</td>
<td>II</td>
<td>Terminated</td>
<td>NCT01647308</td>
</tr>
<tr>
<td>Hyperlipoproteinemia type 1</td>
<td>Pharmaceuticals</td>
<td>ISIS 304B01 (ISIS-APOCIIIRx)</td>
<td>IV</td>
<td>II</td>
<td>Terminated</td>
<td>NCT01647308</td>
</tr>
<tr>
<td>ApoB</td>
<td>Pharmaceuticals</td>
<td>ISIS 304B01 (ISIS-APOCIIIRx)</td>
<td>IV</td>
<td>II</td>
<td>Terminated</td>
<td>NCT01647308</td>
</tr>
</tbody>
</table>

**Abbreviations:** LNPs, lipid nanoparticles; SC, subcutaneous; siRNA, small interfering RNA; TTR, transthyretin.
Ebola (<3 days after infection) using IV LNP injections with siRNA (TKM-Ebola formulation). However, in the later clinical trials, adverse toll-like receptors-mediated immune response presumably provoked by the LNPs was observed in some patients during dose escalation, causing the termination of the studies at Phase I. The adverse effect was seen during initial injections of high doses, but subsequent injections were well tolerated (NCT02041715). Large-scale animal trials are expected to provide solutions to this problem.

Continuous growth of the population infected with HBV and hepatitis C virus urges the development of RNAi-based treatments. Today, a number of efficient small-molecule drugs exist: nucleoside analogs entecavir or tenofovir for HBV and sofosbuvir or simprevir for hepatitis C virus. However, strict adherence to the prescribed daily/weekly schedule is necessary for the success of the treatment, while RNAi acts for months, which represents a significant improvement in quality of life. Arbutus Biopharma Corporation developed LNP-based siRNAs targeting three different loci of the gene encoding for the HBV surface antigen present in chronically infected patients. This preparation is entering a Phase I trial. Targeting this surface antigen is particularly important, as reduction of its expression can lead to ablation of immune suppression and stimulation of T-cell response of the patient. For the treatment of HBV, two Phase II clinical trials led by Arrowhead Research Corporation are presently ongoing, testing the RNAi dynamic conjugate (DPC) ARC-520 in combination with approved nucleoside analogs (NCT02065336 and NCT02349120). In the case of DPC, the duration of the effect is shorter than that achieved with the LNP-based Arbutus formulation, which might be a disadvantage of the otherwise very promising ARC-520.

Cancer
The miRNA miR-34 is a well-known tumor suppressor, which inhibits cell cycle progression and induces cancer cell death. In their Phase I trials and safety and dose-escalation studies, NCT01829971 Mirna Therapeutics used LNPs (Smarticle LNP) for the delivery of MRX34. This treatment has been well tolerated in 52 patients who received two injections per week for months, which represents a significant improvement in quality of life. Arbutus Biopharma Corporation used LNPs for the delivery of MRX34. However, the adverse effect was seen during initial injections of high doses, but subsequent injections were well tolerated (NCT02041715). Large-scale animal trials are expected to provide solutions to this problem.

Another important target for the treatment of cancer is the polo-like kinase 1 (PLK1), a protein that is often overexpressed in cancer and whose inhibition results in reduced cell division. Inhibition of PLK1 expression prevents the tumor cell from completing the cell division, resulting in apoptosis. Arbutus Biopharma Corporation has completed Phase I studies and is currently conducting Phase II trials in patients with gastrointestinal neuroendocrine tumors, adrenocortical carcinoma, and HCC (NCT01437007, NCT01262235, NCT02191878). Phase I trials resulted in a dose-dependent effect and achieved stable disease and partial response in five out of six patients, in addition to a 19.3% reduction in tumor size. This disease model is ideal for LNPs because of the natural biodistribution of the particles in the neuroendocrine tumors. This makes the adrenal cortex and similar structures possible candidates for LNPs. Arbutus Biopharma Corporation is currently evaluating TKM-PLK1 in an expansion cohort with 20 patients who have HCC. This study is designed to evaluate TKM-PLK1’s safety and efficacy in treating HCC patients.

MYC is one of the first discovered classical oncoproteins essential for the growth of many tumors, including HCC. Dicerna is presently conducting Phase I studies with DCR-MYC, a Dicer substrate-based RNAi targeting the MYC oncogene, in combination with proprietary EnCore delivery technology, in 72 patients with various cancers, including both solid and hematological cancers, and particularly HCC (NCT02314052, NCT02110563). Patients undergo IV administration once a week for 2 weeks, followed by a week of rest with the potential for follow-up administration. Tumor penetration is the major issue with the EnCore technology, and this is addressed in the clinical trial.

EphA2 is a cell surface receptor tyrosine kinase involved in neuronal cell migration during the development of embryo and is essentially absent in adult tissues. Its overexpression in cancer is associated with poor clinical outcome. EphA2 knockdown in mice reduced tumorigenicity in breast and pancreatic cancer and resulted in reduced tumor growth in a mouse model of ovarian cancer when injected twice a week during 3 weeks and combined with chemotherapy. MD Anderson Cancer Center is conducting a Phase I study involving 40 patients with advanced solid tumors, undergoing IV-administration of 1,2-dioleoyl-sn-glycero-3-phosphatidylethanolamine neutral liposomes loaded with EphA2 siRNA twice weekly for 3 weeks (NCT01591356). Antineoplastic activity was reported, associated with reduced transcription and translation of EphA2.
Noncancer diseases

Experiments with knockdown of PCSK9 give an excellent example of the gain-of-function approach.\textsuperscript{6,4} Selection of PCSK9 was prompted by clinical cases of genetic disorders with gain of function of this protease causing hypercholesterolemia or, on the contrary, loss-of-function mutations resulting in very low levels of plasma cholesterol. It was further revealed that PCSK9 activity has a strong influence on cholesterol levels through degradation of major hepatic receptors or low density lipoprotein (LDL) clearing receptors in hepatocytes. PCSK9 binds hepatocyte LDL clearing receptors both intracellularly and extracellularly, leading to their lysosomal degradation.\textsuperscript{65,66} Patients treated with siRNA against PCSK9 formulated in LNP had lower LDL-C levels by 60\% in the absence of statins, an effect that was sustained for more than 3 months with a single dose of 10 mg/kg (NCT02314442). This success story can be considered the first published clinical data proving the efficacy of a new class of well-tolerated drugs. LDL levels can potentially be effectively controlled by other classes of drugs such as statins, fibrins, bile acid binding resins, niacin, and cholesterol adsorption inhibitors. Moreover, monoclonal antibodies against PCSK9 have also been found to be almost as effective as siRNA.\textsuperscript{67} However, there is a strong opinion that RNAi-based drugs will find a niche even in this competitive market, since existing treatments leave a significant number of patients with poorly controlled LDL levels, even at the highest tolerated doses of existing drugs.

Other tricky targets are apolipoprotein C3 (apoC3) in hypertriglyceridemia and angiopoietin-like 3 protein (ANGPTL3) in the genetic forms of mixed hyperlipidemia and severe hypertriglyceridemia.\textsuperscript{68} The strategy for the selection of apoC-III for RNAi targeting resembles that implemented in the selection of PCSK9. ApoC-III is located on the surface of triglyceride-rich lipoproteins, including very low density lipoprotein (VLDL), chylomicrons, and their remnants. In two genetic studies, subjects with loss-of-function mutations in the apoC-III gene presented 39\%–44\% lower levels of triglycerides and ~40\% lower risk of coronary heart disease.\textsuperscript{69} Patients with a dysfunctional apoC-III have lower cardiovascular risk. Knocking down apoC-III using antisense oligonucleotides reduced apoC-III and triglycerides but increased the “good” facilitating effect of high density lipoprotein-cholesterol, without inducing hepatic steatosis.\textsuperscript{70} Genetic studies also pointed out the ANGPTL3 gene as a potential target for RNAi intervention. Mutations in this gene cause familial hypobetalipoproteinemia type 2,\textsuperscript{65} and ANGPTL3-deficient patients feature an insulin-sensitive phenotype with lower plasma insulin and glucose levels. This gene encodes a family of secreted proteins expressed predominantly in the liver. Once translated into protein, it is further processed into an N-terminal peptide and a C-terminal fibrinogen chain. The N-terminal chain is a regulator of lipid metabolism and lipoprotein secretion, while the C-terminal chain may be involved in angiogenesis. Silencing ANGPTL3 in cells improves glucose uptake and shifts the secretion of VLDL from VLDL1 to poor VLDL2 during insulin stimulation.\textsuperscript{71}

Primary hyperoxaluria type 1 (PH1) is a rare recessive disorder (5 per 1 million births) caused by a mutation in the alanine glyoxylate aminotransferase (AGT) protein, which is encoded by the AGXT gene and is involved in breakdown of hydroxyproline. AGT deficiency causes buildup of oxalate, the metabolite that characterizes PH1 and causes irreversible kidney damage. Ultimate treatment of PH1 requires both liver and kidney transplant. The strategy of Dicerna was to inhibit the liver enzyme glycolate oxidase (GO), which is responsible for converting glycolate into glyoxylate, the precursor of oxalate. LNP RNAi inhibition of GO in a mouse knockout model of PH1 has nearly normalized oxalate levels. In primates, 85\% reduction of GO activity was achieved with 0.3 mg/kg of siRNA, an encouraging result for future Phase I clinical trials. At present, there are no small-molecule inhibitors of GO, and due to the orphan status of the disease, such drugs are not expected to appear in the near future. Hence, RNAi therapy gives a real opportunity for the treatment of this rare disease.

Finally, there are targets that present direct pathology-causing proteins. For example, transthyretin (TTR) is implicated in a rare genetic disease caused by amyloidosis of TTR (ATTR).\textsuperscript{72,73} A mutated variant of this protein causes amyloid deposition in nerve endings and in the heart. However, it is synthesized by the liver and, hence, is an accessible target for siRNA. Therefore, choosing TTR as a drug target is very straightforward. In patients, LNP formulations ALN-TTR01 and ALN-TTR02 suppressed the production of both mutant and nonmutant forms of TTR, establishing proof of concept for RNAi therapy targeting mRNA transcribed from a disease-causing gene (NCT01148953 and NCT01559077). This project is now in Phase III clinical trials, the most advanced stage for an LNP-based therapy (NCT01960348). The trials, led by Alnylam Pharmaceuticals, will serve to evaluate efficacy and safety, with a goal of achieving improved neuropathy impairment scores over placebo with 0.3 mg/kg administration of patisiran every 3 weeks for 18 months in up to 200 patients (NCT01960348).\textsuperscript{46} This project is in the discovery stage; however, if successful,
it can provide a cure for preeclampsia, a disease with unmet efficacious treatment options.\textsuperscript{74}

**Conclusion**

It can be concluded that the present techniques of RNA delivery using LNPs guarantee effective knockdown of any RNA target in the liver. Moreover, there are minimal adverse effects related to the delivery vehicle or the siRNAs themselves. Therefore, the success of siRNA-based drug development in the liver depends mostly on proper target selection. The last 3 years were extremely productive in translation of fundamental studies and preclinical research of RNAi-based therapies into clinical trials. Research in the fields of cancer and antiviral therapies demonstrated the safety and efficacy of an approach based on LNP delivery of siRNA in Phase I/II clinical trials, paving the road for RNAi therapies for the treatment of genetic and metabolic diseases. Alnylam Pharmaceuticals’ PCSK9 studies have demonstrated a competitive edge over existing small molecules and biological intervention in the treatment of hypercholesterolemia. The TTR program is anticipated to receive the first Food and Drug Administration approval for clinical application in the nearest future. Urgent unmet medical needs, particularly in the treatment of patients with viral infections and patients with refractive aggressive cancers, stimulate the development of novel delivery strategies. There is no doubt that we are at the verge of transformation of medical practice by a widespread application of RNAi-based treatment for many human disorders.

**Acknowledgments**

This work was supported by the Russian Scientific Foundation (grant no 14-34-00017). The authors are grateful to Dominique Leboeuf for critical reading of the manuscript.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


